İdiyopatik pulmoner fibrozis hastalarında Hepsidinin sistemik inflamasyon ve anemi ile ilişkisi

Hepcidin, a biomarker produced by hepatocytes, is elevated in chronic disease anemia and inflammation. This study aimed to compare hepcidin levels between patients with Idiopathic Pulmonary Fibrosis (IPF) and healthy controls, and to evaluate the relationship of hepcidin with anemia and systemic inflammation in IPF patients. This study included 82 IPF patients and 31 controls. Hepcidin levels were measured and compared across groups. In IPF patients, the correlation between hepcidin levels and anemia parameters, as well as systemic inflammation markers (ESR, CRP, ferritin, and the Systemic Immune-Inflammation Index), was analyzed. Hepcidin levels were significantly higher in IPF patients compared to controls (37.13±14.92 vs. 25.77±11.25, p<0.001). No significant difference was observed in hepcidin levels between anemic and non-anemic IPF patients (38.25±16.2 vs. 36.7±14.6, p=0.719). There was no significant correlation between hepcidin levels and anemia parameters or systemic inflammation markers in IPF patients, despite differences in ferritin and CRP levels between patients and controls. This study demonstrated that hepcidin levels are elevated in IPF patients independent of anemia and systemic inflammation, suggesting hepcidin as a potential biomarker in IPF.